Sugi Predict

Sugi Predict / Compounds / SCHEMBL2153082

SCHEMBL2153082

SCHEMBL2153082

COC(=O)[C@H](C)NCCNC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.47
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ MALT1 Q9UDY8 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ CTSS P25774 1/20 0.37
▸ CTSK P43235 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14206399 1.00 CA12 (0.50) CA12CA14MEN1GAAKMT2A
SCHEMBL9435405 0.85 KMT2A (0.58) CA12MEN1GAAKMT2ATDP1
SCHEMBL28888489 0.85 KMT2A (0.58) CA12MEN1GAAKMT2ATDP1
SCHEMBL12659810 0.84 MEN1 (0.46) CA12CA14MEN1GAAKMT2A
SCHEMBL13613755 0.83 CA12 (0.44) CA12CA14MEN1GAAKMT2A
SCHEMBL7460122 0.83 CTSL (0.48) CA12CA14MEN1GAAKMT2A
SCHEMBL1319912 0.82 MEN1 (0.54) CA12MEN1GAAKMT2ATDP1
SCHEMBL12189910 0.82 MEN1 (0.51) CA12CA14MEN1GAAKMT2A
SCHEMBL1022917 0.82 KMT2A (0.47) CA12MEN1GAAKMT2ATDP1
SCHEMBL12464151 0.82 TDP1 (0.50) CA12MEN1GAAKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115136-A1 PNA DIAGNOSTIC USE PNA Patent Owners (a/k/a CIG) (US) 2012-05-10 — — US disclosed
EP-1074559-B1 Peptide nucleic acids BUCHARDT OLE (DK) 2011-07-06 — — EP disclosed
US-7378485-B2 Peptide nucleic acids with polyamide-containing backbones BUCHARDT OLE 2008-05-27 — — US disclosed
WO-2008049583-A2 PROCESS FOR SELECTIVELY LOCALIZING ACTIVE INGREDIENTS ON AND IN MITOCHONDRIA AND CORRESPONDING ACTIVE INGREDIENTS Ugichem Gesellschaft für Organische Chemie mbH (AT) 2008-05-02 — — WO disclosed
US-20060160731-A1 Peptide nucleic acids BUCHARDT OLE 2006-07-20 — — US disclosed
EP-1411063-B1 Peptide nucleic acids BUCHARDT OLE (DK) 2006-07-19 — — EP disclosed
US-20060046255-A1 Use of nucleic acid analogues in diagnostics and analytical procedures BUCHARDT OLE 2006-03-02 — — US disclosed
EP-0960121-B1 PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY BUCHARDT DORTE (DK) 2005-11-30 — — EP disclosed
US-20050009041-A1 Peptide nucleic acids and synthetic procedures therefor BUCHARDT OLE (DK) 2005-01-13 — — US disclosed
EP-1411063-A1 Peptide nucleic acids BUCHARDT, Ole (DK) 2004-04-21 — — EP disclosed
US-5736336-A Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility BUCHARDT OLE (DK) 1998-04-07 — — US disclosed
US-5719262-A BIND COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY BUCHARDT OLE (DK) 1998-02-17 — — US disclosed
US-5714331-A INCORPORATING AN AMINOALKYL SIDE CHAIN INTO THE PNA'S WHICH BIND TO COMPLEMENTARY NUCLEOBASE SEQUENCES MORE TIGHTLY TO FORM ?DUPLEXES?; VIRICIDES; ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS EXXON CHEMICAL PATENT INC. 1998-02-03 — — US disclosed
WO-1998003542-A1 PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY BUCHARDT, DORTE (DK) 1998-01-29 — — WO disclosed
EP-0586618-B1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES BUCHARDT DORTE (DK) 1997-07-16 — — EP disclosed
US-5539082-A Peptide nucleic acids NIELSEN PETER E (DK) 1996-07-23 — — US disclosed
EP-0586618-A1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES. BUCHARDT OLE (DK) 1994-03-16 — — EP disclosed
EP-0586474-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT, Ole (DK) 1994-03-16 — — EP disclosed
WO-1992020703-A1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES BUCHARDT OLE (DK) 1992-11-26 — — WO disclosed
WO-1992020702-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT OLE (DK) 1992-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115136-A1 PNA DIAGNOSTIC USE RNASE1, NCL, PABPC4 CA12 98/4885CA14 61/4885MEN1 1735/4885
US-20050009041-A1 Peptide nucleic acids and synthetic procedures therefor POLRMT, CPSF7, RNGTT CA12 3334/4885CA14 2444/4885MEN1 1200/4885
US-20060046255-A1 Use of nucleic acid analogues in diagnostics and analytical procedures ADAR, POLRMT, POLI CA12 210/4885CA14 133/4885MEN1 1103/4885
US-20060160731-A1 Peptide nucleic acids RNGTT, POLM, POLRMT CA12 3022/4885CA14 2627/4885MEN1 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.